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1. Introduction 
 
The relationship between schizophrenia and the problematic use of psychotropic substances, 
including opioid addiction and dependence has been well documented (Batel, 2000). To 
investigate the period prevalence of schizophrenia amongst opioid users at high risk of overdose, 
we conducted an autopsy study using linked and anonymised routine data.  
 
2. Methods 
 
We identified decedents of opioid overdose who died in Wales, a country in the UK with a 
population of approximately 3 million, between 1/1/2012 and 31/12/2015 by searching Office for 
National Statistics (ONS) mortality records. ONS mortality data is coded using the tenth revision of 
the International Statistical Classification of Diseases and Related Health Problems (ICD-10) 
medical coding system (World Health Organisation, 2018). We used codes diagnostic codes F11–
F19 (mental and behavioural disorders due to psychoactive substance use), X40-69 (unintentional 
and intentional poisoning by and exposure to narcotics and psychodysleptics, X85 (assault by 
drugs, medicaments and biological substances) and Y10-19 (poisoning by and exposure to 
narcotics and psychodysleptics) and object codes T40.0-T40.4 to identify opioid overdose deaths. 
 
ONS mortality records were linked with NHS Wales Informatics Service (NWIS) hospital and 
General Practice (GP) datasets. The matching algorithm used to link data brought in to the 
databank was devised at NWIS, and applies deterministic and probabilistic routines in a logical 
sequence. This approach to linkage of routine NWIS data in the Secure Anonymised Information 
Linkage (SAIL) databank allows for consistently accurate matching, demonstrating high specificity 
(>99%) and sensitivity (>95%) (Lyons et al., 2009).  
 
Demographic, identifiable data were then separated from clinical data and records were each 
assigned a unique and encrypted Anonymised Linkage Field (ALF) number. Non-identifiable 
demographic data were then recombined with clinical data by ALF number; meaningless outside 
of the gateway allowing for privacy protection. Once the linked data were anonymised, they were 
analysed in the SAIL gateway (Jones et al., 2014; Lyons et al., 2009).  
 
We searched for schizophrenia related codes in GP and hospital records of decedents of opioid 
overdose within our sample dataset. We used a coding framework previously applied by John and 
colleagues (John et al., 2018). Hospital data were coded using the ICD-10 system (diagnostic codes 
F20-F29), whilst the Read Clinical Terms Version 2 (CTV2) coding framework (NHS Digital, 2018.) is 
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used to record GP episodes including events related to patient care, as well as administrative tasks, 
in Welsh NHS primary care services. We limited our search to capture data related to diagnostic 
codes which were attached to decedent’s hospital and GP records during a period of 36 months 
prior to death. To help contextualise our findings, we also searched for diagnoses of depressive 
disorders using a coding framework devised by John and colleagues (John et al., 2016). We chose a 
36 month observation period prior to overdose death as during this time decedents could be 
considered as being at high risk of opioid overdose.  
 
3. Results 
 
We found that a limited library of diagnostic codes related to schizophrenia had been attached to 
decedent’s hospital and GP records in the 3 years prior to death. A total of seven ICD-10 ‘F’ codes 
describing schizophrenia, schizotypal and delusional disorders were found, and six Read CTV2 
codes describing schizophrenia and schizophrenia spectrum disorder related diagnoses, including 
schizoaffective disorder; paranoid psychosis; and delusional disorder. 
 
We found that one or more of the schizophrenia related ICD-10 and/or Read CTV2 diagnostic 
codes had been attached to the hospital and/or GP records of 19 distinct decedents representing 
over 6% of our sample of decedents (n=312) in the 36 months prior to death. Stratified by year, we 
found that deaths increased over the course of the observation period. In 2012 there were 2 
deaths, 5 in 2013 and 2014 respectively, and 7 in 2015. The decedents did not differ significantly 
from the wider sample in terms of gender ratio (73.68% male vs. 73.08% in the wider sample) and 
mean age at death (39.94 [13.59] vs. 40.72 [11.92]).   
 
Most decedents had received a primary diagnosis at hospital admission or had both GP and 
hospital contact (n=8, 5.12%), whilst a minority were recorded as having GP contact only (n=3, 
0.96%). These results are summarised in Table 1. 
 
Table 1- GP and Hospital data goes here 
 
Over the 36 months, 73.68% of the decedents who received a schizophrenia related diagnosis 
were diagnosed as having schizophrenia, paranoid or unspecified (n=14,). Half (n=7) of these 
overlapped with the next largest group, those who received a diagnosis of schizotypal disorder 
57.89% (n=11). The remaining diagnosis received were 15.79% (n=3) schizoaffective disorder; 
15.79% (n=3) unspecified paranoid state; 10.53% (n=2) unspecified psychotic disorder; and 5.26% 
(n=1) folie à deux.   
 
In terms of intent, we found that 89.47% (n=17) of decedents were found to have died of 
accidental overdose, whilst the remaining deaths (n=2, 10.53%) were of undetermined intent. 
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To help contextualise our findings, we searched for diagnoses of depressive disorder attached to 
GP and hospital records amongst our sample. We found that 8.97% (n=28) of our sample received 
a diagnosis of depressive disorder in the 3 years prior to their death.  
 
4. Discussion 
 
In 2008 McGrath and colleagues (McGrath et al., 2008) carried out a comprehensive systematic 
review of observational studies of the epidemiology of schizophrenia. They identified 34 studies 
concerned with the period prevalence of schizophrenia in the general population. By abstracting 
data from these studies, the authors found an estimated mean annual period prevalence of 
schizophrenia in the general population of 5.7 per 1000 people. Compared to McGrath et al’s 
findings, our data suggests that the prevalence of schizophrenia spectrum disorder in high risk 
opioid users might be over 8 times the prevalence in the general population. However, in utilising 
John et al’s coding framework, we included cases of schizotypal disorder, schizoaffective disorder 
and unspecified paranoid and psychotic states. As such it could be argued that we are not making 
a direct comparison with schizophrenia as defined in McGrath et al’s study. 
 
We found significant overlap between those who received a diagnosis of schizophrenia and those 
who received a diagnosis of schizotypal disorder. These data support the findings of Hjorthøj and 
colleagues (Hjorthøj et al., 2018), who found evidence for an association with opioid drug use and 
conversion of schizotypal disorder to schizophrenia. 
 
The prevalence of depression amongst the total sample did not differ significantly from the 
European average prevalence of depressive disorder as estimated by the authors of the ODIN 
study who found an average overall prevalence of 8.56% (Ayuso-Mateos et al., 2001). 
 
Although these data are inconclusive, they do raise questions related to high risk opioid use and 
schizophrenia. As most deaths were found to be accidental, the first is to what extent do people 
with schizophrenia spectrum disorders self-medicate with opioid drugs and place themselves at 
risk of overdose. There are certainly qualitative data to support the notion that illicit drugs 
including heroin are used by people with schizophrenia to self-medicate (Asher and Gask, 2010). 
Our data contradicts some (of the relatively scarce) quantitative data in this area suggesting that 
high-risk opioid use is either not associated, or is negatively associated with psychotic illness 
(Farrell et al., 2002; Sørensen et al., 2005). Another is whether enough being done to address high 
risk opioid use in patients with schizophrenia.  Certainly, the deleterious effect of comorbid 
substance misuse disorder on health outcomes related to schizophrenia have been recognised for 
some time (Winklbaur et al., 2006), and yet specialist treatment pathways for opioid misuse in 
schizophrenic patients appear to have received little research attention or investment. Our sample 
included only high-risk opioid users who unfortunately died due to overdose, and so it is likely that 
high risk opioid use in this group, who are already known to suffer high levels of premature death, 
is more common than our sample suggests.  
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The authors welcome further research to address these questions and further investigate the 
relationship between schizophrenia and high-risk opioid use. 
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Table 1- GP and Hospital data  
GP and hospital record 
codes 
n=312 
 n % 
GP Episode only 3 0.96 
Hospital Admission only 8 2.56 
Both GP and Hospital 8 2.56 
Total 19 6.09 
 
 
Table 1: Descriptive data and between group differences 
Variable Participant group 
Controls n = 65 SAD n = 18 t d 
Gender (% female) 84.62% 67.86% - - 
Age  
Mean (SD) 
32.74 (11.32) 30.07 (10.47) -1.07  
p = 0.29 
d = 0.24 
SRAS Median (SD) 91 (32.96) 124 (23.26) 4.71 
p = 0.001 
d = 1.13 
CDS- II Median (SD) 46 (11.57) 54.5 (9.54) 2.78 
p = 0.007 
d = 0.63 
CDS-II 
Sub-scales 
 
 
LOC 
Median 
(SD) 
18 (5.46) 
22 (5.23) 2.75 
p = 0.007 
d = 0.62 
Personal 
Control 
Median 
(SD) 
16 (5.72) 18 (6.86) 0.34 
p = 0.73 
d = 0.07 
Stability 
Median 
(SD) 
11 (5.4) 16 (3.7) 2.9 
p = 0.005 
d = 0.68 
(SD)=Standard Deviation; SPIN=Social Phobia Inventory; SRAS=Social Responsibility Attitudes 
Scale; CDS-II=Causal Dimension Scale; LOC=Locus of Control 
Table 2: Regression coefficients for demographic and psychometric variables 
Predictor Variables All Participants 
n = 83 
 β SE t p 
Group* 1.45 
 
0.46 3.14 0.002 
CDS-II LOC 0.03 0.05 0.62 0.54 
CDS-II Stability 0.25 
 
0.05 4.55 0.001 
CDS-II Total -0.006 0.03 -0.21 0.84 
*Control group used as reference category. CDS-II = Causal Dimension Scale 2nd Revision; LOC = 
Locus of Control; PC = Personal Control. 
 
Table 3: Descriptive statistics for cases (n = 18) 
 Age* SPIN SRAS APQ SFA SAFE PEPQ-
R 
M 30.07 52 136.5 121.5 35 104.5 75.5 
SD 10.47 10.29 16.3 15.98 6.72 17.44 23.22 
Range 17-
53 
35-
67 
110-
166 
82-
140 
23-
44 
66-
131 
9-131 
M=Median Average (Mean Average for Age*); SD=Standard Deviation. SPIN = Social Phobia 
Inventory; SRAS = Social Responsibility Attitudes Scale, APQ = Anticipatory Processing 
Questionnaire; SFA = Self-Focussed Attention scale; SAFE = Subtle Avoidance Frequency 
Examination; PEPQ-R = Post-Event Processing Questionnaire-Revised. 
 
Table 4: Pearsons’s product moment correlation 1 
 Age Gender Meds SPIN SRAS APQ SFA SAFE PEPQ-R 
Age  -0.09 0.10 0.41 0.13 0.21 -0.02 0.09 -0.39 
Gender* -0.09  -0.08 0.25 0.60** 0.18 0.48* 0.24 0.15 
Meds** 0.10 -0.08  -0.22 0.34 0.17 -0.06 0.25 0.34 
SPIN 0.41 0.25 -0.22  0.47* 0.14 0.14 0.20 -0.23 
SRAS 0.13 0.60** 0.34 0.47*  0.32 0.19 0.47* 0.09 
APQ 0.21 0.18 0.17 0.14 0.32  0.08 0.24 0.41 
SFA -0.02 0.48* -0.06 0.14 0.19 0.08  0.29 -0.07 
SAFE 0.09 0.24 0.25 0.20 0.47* 0.24 0.29  -0.11 
PEPQ-R -0.39 0.15 0.34 -0.23 0.09 0.41 -0.07 0.11  
*Gender 1= Female;** Meds 1 = currently using prescribed anti-anxiety medication. SPIN = Social 2 
Phobia Inventory; SRAS = Social Responsibility Attitudes Scale, APQ = Anticipatory Processing 3 
Questionnaire; SFA = Self-Focussed Attention scale; SAFE = Subtle Avoidance Frequency 4 
Examination; PEPQ-R = Post-Event Processing Questionnaire-Revised.  5 
*p < .05, **p < .01, ***p < .001 6 


